Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, SWTX, NARI, MORF, KURA, and represent 66.43% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$339M), ASND (+$14M), AZN (+$11M), NARI (+$8.6M), LNTH (+$8.6M), Nanostring Technologies (+$7.8M), PMVP (+$6.6M), ESTA (+$6.5M), PTGX (+$6.5M), SWTX (+$6.1M).
- Started 21 new stock positions in SPY, AZN, GBT, AUPH, LNTH, ATHX, BEAM, CALA, Bridgebio Pharma, NSTG. RLAY, BPMC, CRSP, Nanostring Technologies, KRTX, VRDN, CELU, CNTX, HZNP, PMVP, ASND.
- Reduced shares in these 10 stocks: SAVA (-$15M), Arena Pharmaceuticals (-$9.3M), BBIO (-$8.2M), MRNA (-$7.6M), NVAX (-$7.2M), CYTK (-$6.6M), CERE (-$5.4M), ACRS (-$5.2M), ARYD, SNDX.
- Sold out of its positions in ARKG, ALDX, Arena Pharmaceuticals, BBIO, SAVA, CYTK, Environmental Impact Acqu, INO, NTLA, IOVA. MRTX, MRNA, NVAX, PRCT, RFL, SEER, SNDX, ARYD, CVAC.
- Affinity Asset Advisors was a net buyer of stock by $379M.
- Affinity Asset Advisors has $625M in assets under management (AUM), dropping by 126.98%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Companies in the Affinity Asset Advisors portfolio as of the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 54.2 | $339M | NEW | 750k | 451.64 | |
| Springworks Therapeutics (SWTX) | 3.7 | $23M | +36% | 407k | 56.44 | |
| Inari Medical Ord (NARI) | 3.2 | $20M | +76% | 220k | 90.64 | |
| Morphic Hldg (MORF) | 3.0 | $19M | +16% | 466k | 40.15 | |
| Kura Oncology (KURA) | 2.4 | $15M | +65% | 924k | 16.08 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.3 | $14M | NEW | 120k | 117.36 | |
| Chinook Therapeutics (KDNY) | 2.2 | $14M | +52% | 845k | 16.36 | |
| Protagonist Therapeutics (PTGX) | 2.0 | $12M | +113% | 516k | 23.68 | |
| Establishment Labs Holdings Ord (ESTA) | 1.9 | $12M | +125% | 175k | 67.39 | |
| Travere Therapeutics Note 2.500% 9/1 (Principal) | 1.8 | $12M | +57% | 11M | 1.04 | |
| Astrazeneca Sponsored Adr (AZN) | 1.7 | $11M | NEW | 160k | 66.34 | |
| Zentalis Pharmaceuticals (ZNTL) | 1.5 | $9.6M | +76% | 208k | 46.14 | |
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 1.4 | $8.6M | NEW | 155k | 55.31 | |
| Nanostring Technologies Note 2.625% 3/0 (Principal) | 1.2 | $7.8M | NEW | 7.0M | 1.11 | |
Setup an alertAffinity Asset Advisors will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Madrigal Pharmaceuticals (MDGL) | 1.2 | $7.4M | +15% | 75k | 98.12 | |
| Arya Sciences Acquisitn Corp Class A Ord Shs (ARYE) | 1.1 | $6.8M | 703k | 9.72 | ||
| Repare Therapeutics Ord (RPTX) | 1.1 | $6.7M | +72% | 469k | 14.24 | |
| Pmv Pharmaceuticals Call Option (PMVP) | 1.1 | $6.6M | NEW | 317k | 20.82 | |
| Nanostring Technologies (NSTG) | 1.0 | $6.0M | NEW | 172k | 34.75 | |
| Vincerx Pharma Com New (VINC) | 0.9 | $5.5M | +21% | 1.4M | 4.00 | |
| Rocket Pharmaceuticals (RCKT) | 0.8 | $4.8M | +81% | 300k | 15.86 | |
| Bridgebio Pharma Note 2.250% 2/0 (Principal) | 0.7 | $4.7M | NEW | 10M | 0.47 | |
| Bridgebio Pharma Note 2.500% 3/1 (Principal) | 0.7 | $4.4M | 7.5M | 0.58 | ||
| Celldex Therapeutics Com New (CLDX) | 0.7 | $4.3M | +25% | 125k | 34.06 | |
| Bellus Health Com New (BLU) | 0.7 | $4.1M | +20% | 600k | 6.88 | |
| Cymabay Therapeutics (CBAY) | 0.6 | $4.0M | +13% | 1.3M | 3.11 | |
| Crispr Therapeutics Namen Akt Call Option (CRSP) | 0.6 | $3.5M | NEW | 55k | 62.76 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 0.5 | $3.2M | NEW | 30k | 105.20 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.5 | $3.0M | 300k | 9.91 | ||
| Medicus Sciences Acquisition Cl A Shs (MSAC) | 0.5 | $2.9M | 300k | 9.78 | ||
| Travere Therapeutics (TVTX) | 0.4 | $2.6M | +100% | 100k | 25.77 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.4 | $2.5M | -68% | 70k | 35.01 | |
| Xenon Pharmaceuticals (XENE) | 0.4 | $2.4M | -46% | 80k | 30.57 | |
| Nautilus Biotechnology (NAUT) | 0.4 | $2.4M | -46% | 559k | 4.34 | |
| Global Blood Therapeutics In (GBT) | 0.4 | $2.4M | NEW | 70k | 34.64 | |
| Relay Therapeutics Call Option (RLAY) | 0.4 | $2.2M | NEW | 75k | 29.93 | |
| Aurinia Pharmaceuticals Call Option (AUPH) | 0.3 | $2.2M | NEW | 175k | 12.38 | |
| Aclaris Therapeutics (ACRS) | 0.3 | $1.7M | -75% | 100k | 17.24 | |
| Beam Therapeutics Call Option (BEAM) | 0.3 | $1.7M | NEW | 30k | 57.30 | |
| Context Therapeutics (CNTX) | 0.3 | $1.7M | NEW | 778k | 2.17 | |
| Cyclacel Pharmaceuticals (CYCC) | 0.2 | $1.2M | 400k | 3.05 | ||
| Lianbio Sponsored Ads (LIAN) | 0.2 | $1.2M | +348% | 325k | 3.71 | |
| Science 37 Holdings (SNCE) | 0.2 | $1.2M | +47% | 221k | 5.35 | |
| Karuna Therapeutics Ord (KRTX) | 0.2 | $951k | NEW | 7.5k | 126.80 | |
| Miragen Therapeutics (VRDN) | 0.1 | $925k | NEW | 50k | 18.50 | |
| Athersys Put Option (ATHX) | 0.1 | $858k | NEW | 1.4M | 0.61 | |
| Renovacor (RCOR) | 0.1 | $846k | +59% | 200k | 4.24 | |
| Curis Com New (CRIS) | 0.1 | $833k | -79% | 350k | 2.38 | |
| Celularity Com Cl A Put Option (CELU) | 0.1 | $697k | NEW | 80k | 8.71 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $586k | -84% | 65k | 8.98 | |
| Calithera Biosciences (CALA) | 0.1 | $404k | NEW | 1.0M | 0.40 | |
| Immatics *w Exp 07/01/202 (IMTXW) | 0.1 | $328k | 187k | 1.75 | ||
| Hyperfine Com Cl A (HYPR) | 0.0 | $270k | 76k | 3.55 | ||
| Blueprint Medicines (BPMC) | 0.0 | $127k | NEW | 2.0k | 63.88 | |
| Renovacor *w Exp 99/99/999 (RCOR.WS) | 0.0 | $26k | 75k | 0.35 | ||
| Medicus Sciences Acquisition *w Exp 02/12/202 (MSACW) | 0.0 | $14k | 33k | 0.42 | ||
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2022 Q1 filed May 13, 2022
- Affinity Asset Advisors 2021 Q4 filed Feb. 11, 2022
- Affinity Asset Advisors 2021 Q3 filed Nov. 12, 2021
- Affinity Asset Advisors 2021 Q2 filed Aug. 13, 2021
- Affinity Asset Advisors 2021 Q1 filed May 14, 2021
- Affinity Asset Advisors 2020 Q4 filed Feb. 12, 2021